Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 876 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at Work as a Key Step towards Protecting the Cancer Workforce and Ensuring High-Quality... MOST POPULAR Cancer in My Community: Working to Expand Access to Clinical Trials... September 22, 2022 How to Make the Most of Your Patient Portal During Cancer November 24, 2021 EMA Recommends Extension of Therapeutic Indications for Durvalumab to Patients with... August 2, 2024 En gran cantidad de casos el exito o examen experto os... August 21, 2023 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Tislelizumab HGTV Star Hilary Farr Shares Breast Cancer Battle CAR22 Shows Durable Efficacy After a Single Infusion in Patients with... Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic...
